Nutriband Inc (NTRB)
3.55
-0.10
(-2.74%)
USD |
NASDAQ |
Apr 26, 14:25
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 27.81M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -2.14% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 13.33 |
| Price to Book Value | 4.869 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.3873 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 95.27% |
Profile
| Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products. |
| URL | https://www.nutriband.com |
| Investor Relations URL | N/A |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Jun. 07, 2024 (est.) |
| Last Earnings Release | Dec. 13, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products. |
| URL | https://www.nutriband.com |
| Investor Relations URL | N/A |
| HQ State/Province | Florida |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Equity Style | Small Cap/Growth |
| Next Earnings Release | Jun. 07, 2024 (est.) |
| Last Earnings Release | Dec. 13, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |